Redx Pharma plc Appointment of NED and changes to Board committees (1361V)
August 05 2020 - 1:00AM
UK Regulatory
TIDMREDX
RNS Number : 1361V
Redx Pharma plc
05 August 2020
REDX PHARMA PLC
("Redx" or "the Company")
Appointment of Non-Executive Director and changes to Board
committees
Alderley Park, 5 August 2020 Redx Pharma (AIM:REDX), the drug
discovery and development company focused on cancer and fibrosis,
is pleased to announce, following the successful completion of the
loan note fundraising and receipt of funds, the appointment of
Thomas ("Tom") Burt as a Non-Executive Director with effect from 4
August 2020. Tom brings extensive investment experience in the
sector to his role at Redx and will represent Sofinnova on the
Board of Directors under the terms of the Subscription for shares
by Sofinnova Crossover 1 SLP ("Sofinnova").
Tom has been a Partner in the Crossover fund at Sofinnova
Partners since its inception in 2017. Prior to this, he was a
Research Analyst covering UK healthcare and life science equities
at Peel Hunt, joining in 2015 after six years as an Investment
Director at specialist life science investors; Ares Life Sciences
and Novo Holdings. Before this, he spent four years in the
Healthcare Investment Banking team at Piper Jaffray & Co. Tom
holds an Engineering Doctorate from UCL in Biochemical Engineering
& Bioprocess Leadership, an MSc in Biochemical Engineering and
a BSc in Biotechnology.
Iain Ross, Chairman of the Board of Redx commented : "We are
delighted to welcome such an experienced director onto the Redx
Board. I am looking forward to working with Tom and to ensuring
that we grow Redx into a substantive biotech company."
Tom Burt commented: " Redx is a company led by a highly talented
management team with a proven track record for success, developing
drugs in areas of high unmet medical need. I am pleased to be
joining the board as a non-executive director and helping the
Company drive forward its next phase of growth."
Board Committee Changes
Following the enlargement of the board, and with effect from 4
August 2020, Iain Ross will step down from his membership of the
Remuneration and Audit & Governance committees. Sarah Gordon
Wild will join these committees as an independent Non-Executive
Director with effect from the same date.
Additional information:
The following information is disclosed pursuant to Schedule Two
paragraph (g) of the AIM Rules for Companies:
Thomas Henry Burt, aged 40, is currently a director of:
-- Sofinnova Crossover 1 SLP
He does not currently hold any ordinary shares in the
Company.
For further information, please contact:
Redx Pharma Plc T: +44 1625 469
918
Iain Ross, Chairman
Lisa Anson, Chief Executive
SPARK Advisory Partners Limited (Nominated Advisor) T: +44 20 3368
3550
Matt Davis/Henry Todd/Adam Dawes
WG Partners LLP (Broker) T: +44 20 3705
9330
Claes Spång/ Chris Lee/ David Wilson
FTI Consulting T: +44 20 3727
1000
Simon Conway/Ciara Martin
About Redx Pharma Plc
Redx is a UK based biotechnology company whose shares are traded
on AIM ( AIM:REDX ). Redx's vision is to become a leading biotech
focused on the development of novel precision medicines that have
the potential to transform treatment in oncology and fibrotic
diseases.
If you would like to sign up to regular alerts from Redx Pharma,
please follow this link
https://www.redxpharma.com/investors/email-alerts/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOAQZLFBBVLZBBE
(END) Dow Jones Newswires
August 05, 2020 02:00 ET (06:00 GMT)
Redx Pharma (LSE:REDX)
Historical Stock Chart
From Apr 2024 to May 2024
Redx Pharma (LSE:REDX)
Historical Stock Chart
From May 2023 to May 2024